-

-
3,3’,5,5’-Tetramethylbenzidine ; CAS# / EC#:54827-17-7OPD TMB [查看]
-
http://m.baichuan365.com/Products/3355SJJLBA_453.html
-

-
3,3’,5,5’-Tetramethylbenzidine dihydrochloride; CAS# / EC#:64285-73-0 OPD TMB-2HCL 水溶性較TMB好[查看]
-
http://m.baichuan365.com/Products/3355SJJLBAEYSY.html
-

-
N-(3-Sulfopropyl)-3,3’,5,5’-tetramethylbenzidine sodium salt ; CAS# / EC#:102062-36-2 TMBTMB-PS [查看]
-
http://m.baichuan365.com/Products/N3HBJ3303955SJJLBANY.html
-

-
2,3,5-Triphenyltetrazolium chloride; CAS# / EC#:298-96-4TMB-2HCL TTC [查看]
-
http://m.baichuan365.com/Products/HSZ235SBJLHSDZ.html
-
![3,3'-[1-(苯氨酰基)-3,4-四氮唑]-二(4-甲氧基-6-硝基)苯磺酸鈉 3,3'-[1-(苯氨酰基)-3,4-四氮唑]-二(4-甲氧基-6-硝基)苯磺酸鈉](http://m.baichuan365.com/UploadFiles/Others/product_no_pic.gif)
-
Sodium3,3'-[1-(phenylamino)carbonyl]-3,4-tetrazolium-bis(4-methoxy-6-nitro)benzenesulfonic acid; CAS# / EC#:111072-31-2TMB-PS XTT 體外細胞增殖、藥敏檢測等細胞活性檢測[查看]
-
http://m.baichuan365.com/Products/330391BAXJ34SDZE4JYJ.html
-

-
TMB 3,3',5,5'-Tetramethylbenzidine CAS:54827-17-7 級別/純度 ;[查看]
-
http://m.baichuan365.com/Products/3355SJJLBA_2.html
-

-
TMB-PS CAS:102062-36-2 級別/純度>99.0%;[查看]
-
http://m.baichuan365.com/Products/N3HBJ3355SJJLBANY.html
-

-
TMB .2HCl 3,3',5,5'-Tetramethylbenzidine dihydrochloride CAS:64285-73-0 級別/純度>99.0%, Advanced;[查看]
-
http://m.baichuan365.com/Products/3355SJJLBAYSY_2.html
-

-
染料EB(溴化乙錠)的新型替代品,無毒無致使癌副作用 CAS: 級別/純度>99.0%;[查看]
-
http://m.baichuan365.com/Products/GeneFindrTM.html
-

-
Litmus CAS:1393-92-6 級別/純度 ;[查看]
-
http://m.baichuan365.com/Products/SR.html
-

-
TMB;EC #/ CAS: 54827-17-7;[查看]
-
http://m.baichuan365.com/Products/3355Tetramethylbenzi.html
-

-
TMB;EC #/ CAS: 54827-17-7;[查看]
-
http://m.baichuan365.com/Products/3355Tetramethylbenzi_1028.html
-

-
MTMC Standard CAS#:1129-41-5 品牌:wako;訂貨號:131-06821 類別:wako農藥標準品[查看]
-
http://m.baichuan365.com/Products/SMWBZP.html
-

-
Varian 920-LC 高效液相色譜儀以及Varian PursuitTM PAH 色譜柱,應用美國EPA頒布的8310 方法,在15 分鐘內快速地分離分析18 種PAHs 混合物。不僅大大節約了試劑和時間的消耗,同時提高了分析通量,相對常規法,一次分離分析更多PAHs 化合物。上海西寶生物科技有限公司提供多種多環芳烴標準品和多環芳烴混合標準溶液[查看]
-
http://m.baichuan365.com/Projects/dhftpahsjcjjfa.html
-

-
免疫檢查點抑制劑(CPI)雖革新了腫瘤治療格局,但PD-1/PD-L1抗體單藥治療僅能使部分患者獲益。在宮頸癌領域,即使PD-L1陽性患者接受pembrolizumab治療的客觀緩解率(ORR)不足20%,而PD-L1陰性患者幾乎無響應。與此同時,PI3K-AKT-mTOR通路的異常激活在多種腫瘤中被證實可促進免疫逃逸,臨床前研究顯示mTOR抑制劑能通過調節腫瘤微環境(TME)增強PD-1抗體療效,但缺乏臨床證據支持。[查看]
-
http://m.baichuan365.com/Article/20250626_industrialnews_1.html